Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui
J
J
López
L
L
Paniagua
I
I
Intxausti
J J
JJ
Maíz
O
O
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D001927:Brain Diseases / Q000150:complications / Q000188:drug therapy*; D054022:Cerebrum; D006801:Humans; D000069285:Infliximab; D008297:Male; D010291:Paresis / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab